Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Advanced Heart Failure and Transplant
For patients acutely decompensated with ACC Stage C-D, NYHA 3-4, probable INTERMACS 4, how do you decide between MCS devices like CCM Barostim or potentially LVAD?
What are hemodynamic indices that would sway you between MCS or foregoing it?
Related Questions
Given findings from the LIFE trial, are there any benefits in using Entresto over valsartan alone in HFrEF patients?
Is there a role for aspirin 81 mg daily in patients with nonischemic dilated cardiomyopathy with reduced EF?
What are standard selection criteria for patients who are eligible for heart transplantation?
What are some immunosuppression regimens to consider in a patient with refractory cardiac sarcoidosis?
Would you ever consider switching a patient with an LVAD from warfarin to Eliquis, such as in the setting of recurrent GI bleeds?
What are the best techniques to reduce POCUS artifact and increase the diagnostic accuracy of lung ultrasound?
What are your first-line vasopressors of choice for the management of acute severe aortic regurgitation and persistent hypotension/shock?
Should an ischemic evaluation be considered in the diagnostic work-up for new-onset diastolic heart failure/HFpEF in patients without clear anginal symptoms?
Do you ever consider sodium supplementation to augment diuresis in patients hospitalized with decompensated heart failure, as discussed in a recent systematic review and meta-analysis?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?